| レジメン名 | IRIS＋Bmab |
|---|---|
| 薬品名 | ベバシズマブBS+イリノテカン＋エスワンタイホウ |
| 一般名 | ベバシズマブ+イリノテカン＋テガフール・ギメラシル・オテラシルカリウム配合剤 |
| 対象疾患 | 切除不能結腸・直腸癌 |

作成日 2021.1.25
最終更新日 2021.1.25

| day | | | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 投与スケジュール | | | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | ● | 休 | 休 | 休 | 休 | 休 | 休 | 休 | 休 | 休 | 休 | 休 | 休 | 休 |
| イリノテカン | CPT-11 | 100mg/㎡ | ★ | | | | | | | | | | | | | | ★ | | | | | | | | | | | | | |
| エスワンタイホウ | S-1 | 80～120mg/日 | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | ★ | | | | | | | | | | | | | |
| ベバシズマブBS | Bmab | 5mg/kg | ★ | | | | | | | | | | | | | | ★ | | | | | | | | | | | | | |
| エスワンタイホウはday1の夕食後からday15の朝食後まで服用 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

1日目、15日目

| 薬剤名・用法 | 規格・容量 | 数量 | 単位 | 投与時間 |
|---|---|---|---|---|
| Rp.1 | | | | |
| 生理食塩液100mL | 100mL | 1 | B | |
| 血管確保用 | | | | |
| | | | | |
| Rp.2 | | | | 15minでdiv |
| アロキシ静注0.75mg | 5mL | 1 | V | |
| デキサート注射液6.6mg | 2mL | 1 | V | |
| デキサート注射液3.3mg | 1mL | 1 | A | |
| 生理食塩液50mL | 50mL | 1 | B | |
| day2,day3/day16,day17にデキサメタゾン8mgを内服 | | | | |
| エスワンタイホウ：day1夕食後～day15朝食後 | | | | |
| | | | | |
| Rp.3 | 初回は90minでdiv、2回目60minでdiv | | | |
| 混注指示必須 | 3回目以降は30minでdiv可 | | | |
| ベバシズマブBS点滴静注400mg | 16mL | | mg | |
| ベバシズマブBS点滴静注100mg | 4mL | | mg | |
| | 5mg/kg | | | |
| 生理食塩液100mL | | 1 | B | |
| | | | | |
| Rp.4 | | | | 90minでdiv |
| イリノテカン点滴静注液100mg | 5mL | | mg | |
| イリノテカン点滴静注液40mg | 2mL | | mg | |
| | 100mg/㎡ | | | |
| 5%ブドウ糖250mL | 250mL | 1 | B | |
| | | | | |

| 薬剤名・用法 | 規格・容量 | 数量 | 単位 | 投与時間 |
|---|---|---|---|---|
| Rp.5 | | | | |
| 生理食塩液50mL | 50mL | 1 | B | 15minでdiv |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

| 薬剤名・用法 | 規格・容量 | 数量 | 単位 | 投与時間 |
|---|---|---|---|---|
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

まつもと医療センターがん化学療法チーム会・薬剤部 2020年4月